Published online November 15, 2004
PEDIATRICS Vol. 114 No. 6 December 2004, pp. e689-e693 (doi:10.1542/peds.2004-1037)

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My File Cabinet Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hsieh, K.-S. Articles by Huang, S.-M. Search for Related Content PubMed PubMed Citation Articles by Hsieh, K.-S. Articles by Huang, S.-M. Related Collections Infectious Disease & Immunity Social Bookmarking                         What's this?

ELECTRONIC ARTICLE

Treatment of Acute Kawasaki Disease: Aspirin’s Role in the Febrile Stage Revisited

Kai-Sheng Hsieh, MD^*,, Ken-Pen Weng, MD^*,, Chu-Chuan Lin, MD^*, Ta-Cheng Huang, MD^*, Cheng-Liang Lee, MD^* and Shih-Ming Huang, MD^*,||

^* Department of Pediatrics, Veterans General Hospital-Kaohsiung, National Yang-Ming University, Kaohsiung, Taiwan
National Defense Medical Center, Taipei, Taiwan
Department of Pediatrics, Zuoying Armed Forces Hospital, Kaohsiung, Taiwan
^|| Department of Pediatrics, Puli Veterans Hospital, Nantou, Taiwan

Objective. To evaluate the effect of treatment without aspirin in the acute phase of Kawasaki disease (KD) and to determine whether it is necessary to expose children to high- or medium-dose aspirin.

Methods. A total of 162 patients who fulfilled the established criteria of acute KD between 1993 and 2003 were included in this retrospective study. All patients were treated with high-dose intravenous immunoglobulin (IVIG; 2 g/kg) as a single infusion without concomitant aspirin treatment. Low-dose aspirin (3–5 mg/kg per day) was subsequently prescribed when fever subsided. Patients who had defervescence within 3 days after the completion of IVIG treatment were classified as the IVIG-responsive group, and those whose fever persisted for >3 days were classified as the IVIG-nonresponsive group. The 162 patients were divided further into 2 groups: those who were treated with IVIG before illness day 5, and those who were treated after illness day 5. We compared the response rate of IVIG therapy, duration of fever, and incidence of coronary artery abnormalities (CAAs) between these groups.

Results. A total of 153 patients were classified into the IVIG-responsive group, and 128 (83.66%) of them had defervescence within 24 hours after completion of IVIG therapy. Nine (5.56%) patients were classified into the IVIG nonresponsive group, and all received additional IVIG (2 g/kg) without aspirin. Six (66.67%) had defervescence within 3 days after additional therapy. Patients in the IVIG-nonresponsive group had a significantly higher incidence of CAAs than those in the IVIG-responsive group (25% vs 2.92%). In the group that was treated before illness day 5 (n = 16), all patients had defervescence within 3 days after IVIG therapy and 13 (81.25%) had defervescence within 24 hours. In the group that was treated after illness day 5 (n = 146), 137 (93.84%) patients had defervescence within 3 days and 115 (78.77%) had defervescence within 24 hours. One (6.67%) patient in the group that was treated before illness day 5 got a new onset of CAAs, as did 5 (3.85%) in the group that was treated after illness day 5. There was no statistically significant difference in the response rate of IVIG therapy, duration of fever, and incidence of CAAs between these 2 groups.

Conclusion. The results of our study indicate that the treatment without aspirin in acute stage of KD had no effect on the response rate of IVIG therapy, duration of fever, or incidence of CAAs when children were treated with high-dose (2 g/kg) IVIG as a single infusion, despite treatment before or after day 5 of illness. We conclude that it seems unnecessary to expose children to high- or medium-dose aspirin therapy in acute KD when the available data show no appreciable benefit in preventing the failure of IVIG therapy, formation of CAAs, or shortening the duration of fever.

---

Key Words: Kawasaki disease • immunoglobulin • coronary aneurysm • aspirin

Abbreviations: KD, Kawasaki disease • IVIG, intravenous immunoglobulin • CAA, coronary artery abnormality

---

Accepted Jul 23, 2004.

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. Senzaki Long-Term Outcome of Kawasaki Disease Circulation, December 16, 2008; 118(25): 2763 - 2772. [Full Text] [PDF]